Inducible hepatic porphyrias are inherited genetic disorders of enzymes of heme biosynthesis. The main clinical manifestations are acute attacks of neuropsychiatric symptoms frequently precipitated by drugs, hormones, or fasting, associated with increased urinary excretion of ␦-aminolevulinic acid (ALA). Acute attacks are treated by heme infusion and glucose administration, but the mechanisms underlying the precipitating effects of fasting and the beneficial effects of glucose are unknown. We show that the rate-limiting enzyme in hepatic heme biosynthesis, 5-aminolevulinate synthase (ALAS-1), is regulated by the peroxisome proliferator-activated receptor ␥ coactivator 1␣ (PGC-1␣). Elevation of PGC-1␣ in mice via adenoviral vectors increases the levels of heme precursors in vivo as observed in acute attacks. The induction of ALAS-1 by fasting is lost in liver-specific PGC-1␣ knockout animals, as is the ability of porphyrogenic drugs to dysregulate heme biosynthesis. These data show that PGC-1␣ links nutritional status to heme biosynthesis and acute hepatic porphyria.
Introduction
The heme biosynthetic pathway in eukaryotic cells is comprised of eight enzymatic steps; the first and the last three enzymes are located in the mitochondria, while the rest are in the cytoplasm ( Figure 1A ). Eighty to ninety percent of total heme in mammals is synthesized in erythroid cells for incorporation into hemoglobin. Regulation of heme biosynthesis in these cells involves the erythroid-specific aminolevulinate synthase (ALAS) gene ALAS-2. In contrast, the housekeeping ALAS gene ALAS-1, also called ALAS-N or ALAS-H, is ubiquitously expressed, given that all nucleated cells must synthesize heme for respiratory cytochromes. The bulk of the nonerythroid-synthesized heme is produced in the liver for various heme proteins, in particular *Correspondence: bruce_spiegelman@dfci.harvard.edumicrosomal cytochromes P450. Because either a deficiency or an excess of heme is toxic to the cell, hepatic heme production has to be tightly controlled, mostly via its rate-limiting step ALAS-1. Accordingly, hepatic ALAS-1 is highly regulated in different contexts to ensure adequate levels of intracellular heme (May et al., 1995) . Inherited mutations in all genes encoding for heme biosynthetic enzymes have been described, except for ALAS-1, and the resulting diseases are referred to as porphyrias (Elder, 1998) . Depending on the specific enzymatic defect, different patterns of overproduction, accumulation, and excretion of intermediates of heme synthesis are observed.
The main clinical manifestations of porphyrias are intermittent attacks of neuropsychiatric dysfunction and/ or sensitivity of the skin to sunlight. The neuropsychiatric syndrome occurs only in those porphyrias in which there is intermittent induction of hepatic ALAS-1 and consequent increased urinary excretion of δ-aminolevulinic acid (ALA). Attacks are characteristically precipitated by drugs such as barbiturates, fasting, and hormones and result in abdominal pain, tachycardia, peripheral motor neuropathies, psychosis, and other mental disturbances (Elder, 1998; Thadani et al., 2000; Thunell, 2000) . Inducible hepatic porphyrias are caused by rare defects in δ-aminolevulinic acid dehydratase (ALAD), porphobilinogen deaminase (PBGD, also known as hydroxymethylbilane synthase), coproporphyrinogen oxidase, and protoporphyrinogen oxidase. The classical names for the corresponding diseases are ALAD deficiency, acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.
Although not definitively proven, historic personalities thought to have suffered from porphyria include King George III (Macalpine and Hunter, 1966) , Friedrich Wilhelm I of Prussia (Macalpine et al., 1968; Pierach and Jennewein, 1999) , and Vincent van Gogh (Bonkovsky et al., 1992; Loftus and Arnold, 1991). Thus, the psychoses arising from their disease potentially influenced the course of the American war for independence and/or the creative genius of van Gogh. Acute attacks of inducible hepatic porphyria are treated by discontinuing exposure to the precipitating agents, heme infusions, and high carbohydrate load. The carbohydrates are typically given as concentrated glucose infusion. Heme directly represses its own biosynthesis in a negative feedback loop (May et al., 1995) . In contrast, the underlying mechanisms of the beneficial effects of carbohydrates are not understood.
Proliferator-activated receptor γ coactivator 1α (PGC-1α) is a coactivator of nuclear receptors and other transcription factors ). In the liver, PGC-1α is induced during fasting, when the liver ceases using glucose as an energy supply and changes to the β-oxidation of fatty Thus, because of the key role of PGC-1α in liver energy homeostasis and the finding that many PGC-1α targets are heme proteins, we investigated the role of PGC-1α in the regulation of hepatic heme biosynthesis by nutrition. We found that PGC-1α is an important factor controlling the expression of ALAS-1 in the fasted and fed liver. Moreover, we showed that hepatic PGC- Figure 1B) . To test the relationship between the regulation of these two genes, Fao rat hepatoma cells, mouse primary hepatocytes, and rat liver in vivo were infected with adenovirus expressing PGC-1α. In all of these systems, ectopic expression of PGC-1α increased ALAS-1 transcript levels in a manner similar to that of glucose-6-phosphatase (Glc6P), a PGC-1α target gene involved in gluconeogenesis (Yoon et al., 2001) (Figures 1C-1E) . In contrast to ALAS-1, none of the other seven genes of the heme biosynthetic pathway were induced by PGC-1α in rat liver ( Figure 1E ).
Insulin and Glucagon Regulation of ALAS-1 Involves PGC-1␣
Regulation of ALAS-1 in fasting and feeding is mediated by the counterregulatory hormones insulin and glucagon (Scassa et al., 1998; Varone et al., 1999) . Insulin treatment of primary mouse hepatocytes reduces basal levels of ALAS-1 mRNA (Figure 2A) . Furthermore, PGC-1α-induced ALAS-1 transcript levels are reduced by insulin, suggesting that PGC-1α is in the pathway of the insulin regulation of ALAS-1 (Figure 2A ). Primary hepatocytes from wild-type and PGC-1α knockout mice (Lin et al., 2004) were used to elucidate the function of PGC-1α in the ALAS-1 induction in fasting, with dexamethasone and forskolin representing the effects of glucocorticoids and glucagon that are elevated when blood glucose levels are low. Induction of ALAS-1 mRNA by these agents was reduced in the PGC-1α knockout hepatocytes as compared to wild-type cells ( Figure 2B) . Similarly, the response of the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and Glc6P to these hormones was blunted. These findings imply that PGC-1α is involved in the fasting/feeding regulation of all three genes.
Insulin Repression of ALAS-1 Is Mediated by FOXO1 and PGC-1␣
In the ALAS-1 promoter, two binding sites for the nuclear respiratory factor-1 (NRF-1) have been identified (Braidotti et al., 1993). NRF-1 is a transcription factor that increases expression of nuclear-encoded mitochondrial genes (Virbasius and Scarpulla, 1994) and is known to be potently coactivated by PGC-1α (Wu et al., 1999) . Thus, NRF-1 is a potential binding partner by which PGC-1α controls ALAS-1 expression. In addition to the NRF-1 site, an insulin-responsive element (IRE) has been defined in the ALAS-1 promoter (Scassa et al., 2001 (Scassa et al., , 2004 , but the identity of transcription factors binding to this element has remained elusive ( Figure 3A) .
Chromatin immunoprecipitation assays in mouse hepatoma cells illustrate that PGC-1α is recruited to both the NRF-1 and the IRE regions ( Figure 3B ). Moreover, PGC-1α recruitment to the IRE region is sensitive . We thus tested the ability of PGC-1α to coactivate the different Forkhead box family members FOXO1, hepatocyte nuclear factor 3α (HNF3α, FOXA1), and HNF3β on the ALAS-1 promoter. As described by Scassa et al., HNF3β increased reporter-gene levels controlled by the ALAS-1 promoter, whereas HNF3α had no effect ( Figure  3C ). However, of the three transcription factors, PGC-1α only coactivated FOXO1 in this context. In addition, merely the FOXO1-PGC-1α-mediated induction of the ALAS-1 promoter was repressed by insulin ( Figure 3C ).
To further characterize the role for FOXO1 in the regulation of the ALAS-1 promoter, we showed direct physical interaction of FOXO1 with the DNA probes containing the ALAS-1 IRE ( Figure 4A, lanes 4-7) and NRF-1 with the NRF-1 site ( Figure 4A, lanes 1-3) in electrophoretic mobility shift assays. Site-directed mutagenesis of the FOXO1 site abolished binding of FOXO1 to this element ( Figure 4A , lanes 3 and 7, respectively). The specificity of the FOXO1-IRE complex was confirmed by using an anti-FOXO1 antibody that resulted in a supershift (Figure 4A, lane 6) . Functionally, PGC-1α coactivates both NRF-1 and FOXO1 in reporter-gene assays using the ALAS-1 promoter in mouse H2.35 SV-40-transformed hepatocytes ( Figure 4B) . Mutagenesis of the NRF-1 or the IRE sites reduced the ability of PGC-1α to augment the activity from the ALAS-1 promoter stimulated by NRF-1 and FOXO1, respectively. Moreover, an ALAS-1-promoter allele with a combined mutation of both the NRF-1 and IRE sites is completely insensitive to PGC-1α, strongly suggesting that NRF-1 and FOXO1 are the major binding partners of PGC-1α in the ALAS-1 promoter.
As shown in Figure 4C , insulin represses induction of ALAS-1-promoter-driven reporter-gene expression by either FOXO1 alone or in combination with PGC-1α. In contrast, a nonphosphorylatable mutant of FOXO1 with three alanines in place of the serine/threonine residues targeted by Akt kinase (termed FOXO1 3A) prevented repression by insulin. Similarly, insulin is unable to inhibit PGC-1α coactivation of FOXO1 3A. This suggests that the insulin repression of the ALAS-1 promoter is controlled by the FOXO1-PGC-1α interaction.
Liver-Specific PGC-1␣ Knockout Animals Have a Blunted Induction of ALAS-1 in Fasting
To investigate whether PGC-1α is a key mediator of the metabolic regulation of ALAS-1 in an in vivo setting, we first examined animals with a total knockout of PGC-1α animals expressing cre recombinase under the control of the albumin promoter ( Figure 5B ). Tissue-specific ablation of PGC-1α in the liver was verified by mRNA analysis ( Figure 5C ). PGC-1α levels in the heart, skeletal muscle (SKM), and brown adipose tissue (BAT) were unaltered. Moreover, liver-specific knockout of PGC-1α did not change the expression of the closely related family member PGC-1β in liver, heart, skeletal muscle, or brown adipose tissue.
In these mice, basal levels of ALAS-1, PEPCK, and Glc6P were not elevated, as was seen in the total knockout ( Figure 5D ). Indeed, ALAS-1 basal expression was significantly lower in the liver-specific PGC-1α knockout as compared to wild-type animals. Moreover, the induction of ALAS-1 and the gluconeogenic genes after 16 hr of fasting was severely blunted in the liver-specific knockout animals compared to wild-type mice ( Figure 5D ). These findings indicate a requirement for PGC-1α in the fasting/feeding regulation of the gluconeogenic genes and, furthermore, imply a key role for PGC-1α in the dietary control of ALAS-1 transcription. Patients suffering from porphyric attacks are given a high carbohydrate load. Thus, in addition to refeeding, fasted mice were i.p. injected with a bolus of glucose (1 g/kg) or glucose (1 g/kg) and insulin (1.0 U/kg) 30 min, 60 min, or 120 min before mice were sacrificed and hepatic PGC-1α and ALAS-1 mRNA levels were determined ( Figure 5E ). Glucose loading reduces ALAS-1 transcript levels 30 min after injection. The combination of glucose and insulin is even more potent in inhibiting fasting-mediated induction of PGC-1α and ALAS-1, supporting the hypothesis that at least part of the bene- Wild-type and liver-specific PGC-1α knockout mice were fasted for 12 hr, and relative transcript levels for PGC-1α, ALAS-1, PEPCK, and glucose-6-phosphatase (Glc6P) were determined by semiquantitative PCR. (E) Glucose reverses fasting-mediated induction of PGC-1α and ALAS-1. Wild-type and liver-specific PGC-1α knockout animals were fasted for 6 hr and subsequently injected with vehicle, glucose, or glucose and insulin. After 30, 60, or 120 min, respectively, mice were sacrificed, livers were harvested, and relative PGC-1α and ALAS-1 expression levels were determined. (F) Phenobarbital induces ALAS-1 independent of PGC-1α. Wild-type and liver-specific PGC-1α knockout animals were injected i.p. with vehicle (saline) or phenobarbital (100 mg/kg). Sixteen hours after injection, livers were harvested, and relative mRNA levels of PGC-1α, ALAS-1, and cytochrome P450 2b10 and 3a11 (Cyp2b10 and Cyp3a11, respectively) were determined by semiquantitative PCR. Data in (A) and (C)-(F) are represented as mean ± standard deviation. *p < 0.05 between wild-type and knockout animals in Student's t test.
ficial effect of glucose in acute porphyric attacks is mediated by the glucose-triggered increase of plasma insulin. ALAS-1 mRNA is not regulated by fasting in the knockout mice, and, thus, no effect of glucose and/or insulin on ALAS-1 transcript levels could be observed.
Taken together, these data strongly suggest that PGC-1α may be involved in fasting-induced acute porphyric attacks. Apart from fasting, certain drugs we chose the barbiturate phenobarbital (PB), a classical drug that precipitates porphyric attacks in patients. As shown in Figure 5F , no significant difference in PB induction of ALAS-1 and the prototypical PB-target genes cytochromes P450 Cyp2b10 and Cyp3a11, two microsomal cytochromes P450 with a heme moiety as prosthetic group, was observed between wild-type and liver-specific PGC-1α knockout animals. These data indicate that the role of PGC-1α in ALAS-1 regulation does not extend universally to all other mechanisms, 
Elevated Expression of PGC-1␣ Causes Acute Attacks in Chemical Porphyria
The consequence of ALAS-1 regulation by PGC-1α in fasting and feeding for acute porphyric attacks was subsequently tested using proporphyrogenic drugs that are known to function by disruption of the pathway of hepatic heme biosynthesis. Two members of this class of chemicals are lead (Pb) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) ( Figure 6A ). Lead intoxication produces symptoms resembling those of acute hepatic porphyria (May et al., 1995) . Because of its ability to replace other ions such as zinc and to block thiol groups, lead inhibits several enzymes in heme biosynthesis, most importantly ALAD. Another drug widely used to induce porphyria in systems that lack the genetic predisposition for this disorder, DDC, causes accumulation of N-methyl protoporphyrin, a potent inhibitor of ferrochelatase (De Matteis et al., 1973) . In gain-of-function experiments, mice were injected i.v. with adenoviral GFP and PGC-1α. These animals were subsequently fasted and treated with vehicle (corn oil) or DDC for 24 hr. DDC did not change adenoviral ex- pression of PGC-1α mRNA ( Figure 6B ). In contrast, ALAS-1 transcript levels were elevated 10-fold in animals that received both PGC-1α adenovirus and DDC ( Figure 6C ). This high induction of ALAS-1 was reflected in the dramatically increased levels of the heme precursors 5-ALA and PBG in their plasma ( Figures 6D  and 6E ), to 9 M and 27 M, respectively. Importantly, these are levels that are seen in acute attacks in mouse models of porphyria. Thus, in wild-type animals with chemical porphyria, elevation of PGC-1α expression in the liver results in accumulation of heme precursors comparable to that classically observed in drug-precipitated acute attacks in genetic mouse models of porphyria (Lindberg et al., 1996, 1999) .
Liver-Specific PGC-1␣ Knockout Animals Are Protected from Chemical Porphyria
The requirement for PGC-1α in fasting-induced porphyria was tested in the liver-specific PGC-1α knockout animals. In fasted wild-type animals treated with lead chloride and DDC for 24 hr, increased ALAS-1 mRNA levels were observed as compared to treatment with their vehicles saline and corn oil, respectively ( Figure  7A ). In contrast, neither lead chloride nor DDC changed endogenous PGC-1α levels (data not shown). As a consequence of the ALAS-1 induction and the chemical block in the biosynthetic pathway, 5-ALA accumulates in plasma after lead and DDC treatment ( Figure 7B ). Since lead and DDC inhibit heme biosynthesis at different steps (Figure 6A) , only DDC elevates PBG levels ( Figure 7C) . Thus, as reported, blocking of heme biosynthesis with porphyrogenic drugs results in a state of latent porphyria in wild-type mice, comparable to the status of patients between attacks, which is characterized by moderately elevated levels of 5-ALA and PBG (De Matteis, 1973) . In an actual acute attack, 5-ALA and PBG levels rise to those observed in the gain-of-function experiment shown in Figure 6D and 6E. Strikingly, lead and DDC completely fail to induce either ALAS-1 mRNA ( Figure 7A ) or plasma 5-ALA (Figure 7B) or PBG levels ( Figure 7C ) in the liver-specific PGC-1α knockout mouse. These data indicate that PGC-1α is absolutely required for animals treated with porphyrogenic drugs to enter a state of latent porphyria.
Discussion
While the biochemical consequences of mutations in the heme biosynthetic pathway are well known, the molecular mechanisms underlying the nutritional regulation of hepatic porphyrias have been poorly understood. Specifically, questions regarding how fasting can precipitate porphyric attacks and why glucose infusions provide therapeutic benefit have remained unanswered. The results presented here provide a clear-cut mechanism, deduced from biochemical and genetic evidence: the transcriptional coactivator PGC-1α is induced in the liver in fasting and potently turns on expression of the ALAS-1 gene in hepatocytes and in liver in vivo. The induction of PGC-1α in fasting has previously been shown to be a consequence of glucagon action and the transcription factor cAMP element binding protein (CREB), which binds directly to the PGC-1α promoter (Herzig et al., 2001 ). In addition, CREB can also directly activate the ALAS-1 promoter (Varone et  al., 1999) .
PGC-1α activates the ALAS-1 promoter by coactivating NRF-1 and FOXO1, both of which directly bind to the ALAS-1 promoter (Figure 6 ). The ability of PGC-1α to positively regulate the ALAS-1 gene and the requirement for PGC-1α in the fasting induction of ALAS-1 together provide a direct explanation for how fasting can provoke an acute attack in an individual with a mutation in the pathway of heme biosynthesis that results in hepatic porphyria. Indeed, adenoviral expression of PGC-1α in mice with chemical inhibition of enzymes of heme biosynthesis results in significantly elevated porphyrin precursor levels reminiscent of acute porphyric attacks. In contrast, the excess production of heme intermediates by porphyrogenic drugs is lost in the liver-specific PGC-1α knockout.
The therapeutic effect of glucose on acute hepatic porphyria is well documented (Robert et al., 1994) Agents that elevate hepatic PGC-1α levels are therefore potentially dangerous for patients with hepatic porphyrias. Accordingly, drugs and foods that induce PGC-1α in the liver should be avoided. Unfortunately, because of the therapeutic high carbohydrate intake, patients with hepatic porphyrias are prone to weight gain. Losing excess weight is very difficult for some of these patients because of fasting-induced acute attacks. Hopefully, our findings described here might lead to the development of more specific treatments for these patients.
Experimental Procedures

RNA Isolation and Analysis
Total RNA was isolated from liver or cultured cells using the Trizol reagent (Invitrogen) according to the manufacturer's protocol. For semiquantitative real-time PCR analysis, 1 g of total RNA was treated with RNase-free DNase and subsequently reverse transcribed with random hexamer primers (Roche Applied Science). Relative mRNA abundance normalized to 18S rRNA levels was determined with the ⌬⌬Ct method after amplification using a iCycler iQ real-time PCR detection system (Bio-Rad) and SYBRGreen (BioRad). Data are represented as mean ± standard deviation. Significance is defined as p < 0.05 in Student's t test.
Animal Experiments
All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee. Animals were fed standard rodent chow and housed in a controlled environment with 12 hr light and dark cycles. For fasting experiments, mice were deprived of food for the indicated amount of time before animals were sacrificed. Drugs (phenobarbital, 100 mg/kg; PbCl 2 , 20 mg/kg; DDC, 10 mg/kg) were injected i.p., and livers and blood were harvested after 16 or 24 hr. All groups consisted of at least three to six mice. Glucose (1 g/kg) and insulin (1.0 U/kg) were injected i.p. into mice that were fasted for 6 hr. Data are represented as mean ± standard deviation. Significance is defined as p < 0.05 in Student's t test.
Generation of Liver-Specific PGC-1␣ Knockout Animals Generation of animals with floxed PGC-1α alleles has been described (Lin et al., 2004) . These mice were crossed with mice that transgenically express cre recombinase under the control of the rat albumin promoter (Jackson Laboratory, strain B6.Cg-Tg(Alb-cre) 21MGn/J) to obtain liver-specific PGC-1α knockout mice. 
Adenoviral Infection
Cloning of Promoter Constructs and Site-Directed Mutagenesis
The rat ALAS-1 promoter (Braidotti et al., 1993) was amplified by PCR and cloned into the pGL3 basic luciferase reporter-gene vector (Promega). Site-directed mutagenesis was performed using overlapping primers. All constructs were verified by sequencing.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays were performed as described (Handschin et al., 2003) . Briefly, wild-type and mutant ALAS-1-promoter fragments were radiolabeled and used as probes together with in vitro-transcribed/translated proteins. Protein-DNA complexes were subsequently separated by polyacrylamide gel electrophoresis. FOXO1 antibody was purchased from Santa Cruz Biotechnology.
Chromatin Immunoprecipitation
Experiments were performed using the Chromatin Immunoprecipitation (ChIP) Assay Kit (Upstate) following the manufacturer's protocol. H2.35 cells were infected with adenoviral GFP and FLAGtagged PGC-1α for 24 hr and treated with vehicle or 10 nM insulin for 12 hr before cells were harvested, DNA-protein complexes crosslinked, and immunoprecipitation reactions performed using anti-FLAG beads (Sigma). After reverse crosslinking, DNA was purified by phenol/chloroform extraction and ethanol precipitation, and relative levels were subsequently analyzed by PCR.
Determination of ALA and PBG Plasma Levels When animals were sacrificed, blood was harvested by cardiac puncture. Blood plasma was purified by centrifugation in heparin tubes (Becton Dickinson) and treated as described (Mendez et al., 1999) . ALA and PBG levels in the plasma were subsequently analyzed by sequential ion-exchange chromatography using columns from the ALA/PBG by Column Test Kit (Bio-Rad) using a modified protocol (Davis and Andelman, 1967). PBG and ALA were absorbed on anion-and cation-exchange resins, respectively. Following elution and conversion to pyrrole in the case of ALA, Ehrlich's reagent was added, and PBG and ALA levels were determined colorimetrically. Data are represented as mean ± standard deviation. Significance is defined as p < 0.05 in Student's t test.
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